Global (United States, European Union and China) Chagas Disease Treatment

Chagas Disease Treatment Comprehensive Study by Type (Acute Chagas Disease, Chronic Chagas Disease), Application (Hospitals, Homecare, Specialty Clinics, Others), Drugs (Benznidazole, Nifurtimox), Treatment (Antiparasitic Treatment, Symptomatic Treatment), Route of Administration (Oral, Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2027

Chagas Disease Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Chagas Disease Treatment Market?

Chagas disease is spread by contact with feces of an infected insect (triatomine) carrying the agent of the disease, a parasite called Trypanosoma cruzi. This parasitic disease is estimated to affect around 6-7 million people worldwide, primarily in rural areas in Latin America. While more common in South America, it has previously been less common in North America. An increasing number of patients of Chagas disease has projected the growth of the global Chagas disease treatment market in the forecast.

Highlights from Chagas Disease Treatment Market Study
AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledHumanigen, Inc (United States), Savant HWP, Inc (United States), Bayer AG (Germany), Eisai Co., Ltd (Japan), Oblita Therapeutics (Belgium), GlaxoSmithKline plc (United Kingdom), Collaborations Pharmaceuticals, Inc (United States), Astellas Pharma Inc (Japan), Sanofi (France) and Pfizer Inc (United States)


Research Analyst at AMA predicts that European and United States Players will contribute to the maximum growth of Global Chagas Disease Treatment market throughout the forecasted period.

Humanigen, Inc (United States), Savant HWP, Inc (United States), Bayer AG (Germany), Eisai Co., Ltd (Japan), Oblita Therapeutics (Belgium), GlaxoSmithKline plc (United Kingdom), Collaborations Pharmaceuticals, Inc (United States), Astellas Pharma Inc (Japan), Sanofi (France) and Pfizer Inc (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Epichem Pty Ltd (Australia), DAIICHI SANKYO COMPANY, LIMITED (Japan), Novartis AG (Switzerland), Kancera AB (Sweden), AstraZeneca (United Kingdom) and Maprimed S.A. (Argentina).

Chagas Disease Treatment Market Segmentation:
ScopeSub-Segments
Application / End UserHospitals, Homecare, Specialty Clinics and Others
TypeAcute Chagas Disease and Chronic Chagas Disease
DrugsBenznidazole,Nifurtimox
TreatmentAntiparasitic Treatment,Symptomatic Treatment
Route of AdministrationOral,Injectable
Distribution ChannelHospital Pharmacies,Retail Pharmacies,Online Pharmacies


On the basis of geography, the market of Chagas Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emergence of Drugs Used to Treat Complications Associated with Chagas Disease Such As Heart-Related Complications and Digestive-Related Complications

Market Growth Drivers:
Large scape Population Movements Mostly from Ruler Urban Areas of the World Have Increased the Geographic Distribution of the Chagas Disease and Increased Number of Patients with Chagas Disease

Challenges:
Low Healthcare Budget in Some Developing

Restraints:
Limited Operating Revenue Opportunities for Research and Development of Targeted Therapies

Opportunities:
Consumption of Uncooked Food Contaminated With Feces and High Demand for Disease-Specific Novel Treatment

Key Target Audience
Chagas Disease Drugs Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Other

On 10th August 2020, Bayer has announced that the United States Food and Drug Administration (FDA) has approved Lampit (nifurtimox) for use in pediatric patients (from birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi.
The FDA is committed to making available safe and effective therapeutic options to treat tropical diseases. The FDA approval is based on results from the Chagas disease in children treated with nifurtimox study, the first part of the largest Phase III program ever conducted in pediatric patients for the treatment of Chagas disease.

Report Objectives / Segmentation Covered

By Type
  • Acute Chagas Disease
  • Chronic Chagas Disease
By Application
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
By Drugs
  • Benznidazole
  • Nifurtimox

By Treatment
  • Antiparasitic Treatment
  • Symptomatic Treatment

By Route of Administration
  • Oral
  • Injectable

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Large scape Population Movements Mostly from Ruler Urban Areas of the World Have Increased the Geographic Distribution of the Chagas Disease
      • 3.2.2. Increased Number of Patients with Chagas Disease
    • 3.3. Market Challenges
      • 3.3.1. Low Healthcare Budget in Some Developing
    • 3.4. Market Trends
      • 3.4.1. Emergence of Drugs Used to Treat Complications Associated with Chagas Disease Such As Heart-Related Complications and Digestive-Related Complications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chagas Disease Treatment, by Type, Application, Drugs, Treatment, Route of Administration, Distribution Channel and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Chagas Disease Treatment (Value)
      • 5.2.1. Global Chagas Disease Treatment by: Type (Value)
        • 5.2.1.1. Acute Chagas Disease
        • 5.2.1.2. Chronic Chagas Disease
      • 5.2.2. Global Chagas Disease Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Homecare
        • 5.2.2.3. Specialty Clinics
        • 5.2.2.4. Others
      • 5.2.3. Global Chagas Disease Treatment by: Drugs (Value)
        • 5.2.3.1. Benznidazole
        • 5.2.3.2. Nifurtimox
      • 5.2.4. Global Chagas Disease Treatment by: Treatment (Value)
        • 5.2.4.1. Antiparasitic Treatment
        • 5.2.4.2. Symptomatic Treatment
      • 5.2.5. Global Chagas Disease Treatment by: Route of Administration (Value)
        • 5.2.5.1. Oral
        • 5.2.5.2. Injectable
      • 5.2.6. Global Chagas Disease Treatment by: Distribution Channel (Value)
        • 5.2.6.1. Hospital Pharmacies
        • 5.2.6.2. Retail Pharmacies
        • 5.2.6.3. Online Pharmacies
      • 5.2.7. Global Chagas Disease Treatment Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Chagas Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Humanigen, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Savant HWP, Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eisai Co., Ltd (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Oblita Therapeutics (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Collaborations Pharmaceuticals, Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Astellas Pharma Inc (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Chagas Disease Treatment Sale, by Type, Application, Drugs, Treatment, Route of Administration, Distribution Channel and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Chagas Disease Treatment (Value)
      • 7.2.1. Global Chagas Disease Treatment by: Type (Value)
        • 7.2.1.1. Acute Chagas Disease
        • 7.2.1.2. Chronic Chagas Disease
      • 7.2.2. Global Chagas Disease Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Homecare
        • 7.2.2.3. Specialty Clinics
        • 7.2.2.4. Others
      • 7.2.3. Global Chagas Disease Treatment by: Drugs (Value)
        • 7.2.3.1. Benznidazole
        • 7.2.3.2. Nifurtimox
      • 7.2.4. Global Chagas Disease Treatment by: Treatment (Value)
        • 7.2.4.1. Antiparasitic Treatment
        • 7.2.4.2. Symptomatic Treatment
      • 7.2.5. Global Chagas Disease Treatment by: Route of Administration (Value)
        • 7.2.5.1. Oral
        • 7.2.5.2. Injectable
      • 7.2.6. Global Chagas Disease Treatment by: Distribution Channel (Value)
        • 7.2.6.1. Hospital Pharmacies
        • 7.2.6.2. Retail Pharmacies
        • 7.2.6.3. Online Pharmacies
      • 7.2.7. Global Chagas Disease Treatment Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chagas Disease Treatment: by Type(USD Million)
  • Table 2. Chagas Disease Treatment Acute Chagas Disease , by Region USD Million (2016-2021)
  • Table 3. Chagas Disease Treatment Chronic Chagas Disease , by Region USD Million (2016-2021)
  • Table 4. Chagas Disease Treatment: by Application(USD Million)
  • Table 5. Chagas Disease Treatment Hospitals , by Region USD Million (2016-2021)
  • Table 6. Chagas Disease Treatment Homecare , by Region USD Million (2016-2021)
  • Table 7. Chagas Disease Treatment Specialty Clinics , by Region USD Million (2016-2021)
  • Table 8. Chagas Disease Treatment Others , by Region USD Million (2016-2021)
  • Table 9. Chagas Disease Treatment: by Drugs(USD Million)
  • Table 10. Chagas Disease Treatment Benznidazole , by Region USD Million (2016-2021)
  • Table 11. Chagas Disease Treatment Nifurtimox , by Region USD Million (2016-2021)
  • Table 12. Chagas Disease Treatment: by Treatment(USD Million)
  • Table 13. Chagas Disease Treatment Antiparasitic Treatment , by Region USD Million (2016-2021)
  • Table 14. Chagas Disease Treatment Symptomatic Treatment , by Region USD Million (2016-2021)
  • Table 15. Chagas Disease Treatment: by Route of Administration(USD Million)
  • Table 16. Chagas Disease Treatment Oral , by Region USD Million (2016-2021)
  • Table 17. Chagas Disease Treatment Injectable , by Region USD Million (2016-2021)
  • Table 18. Chagas Disease Treatment: by Distribution Channel(USD Million)
  • Table 19. Chagas Disease Treatment Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 20. Chagas Disease Treatment Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 21. Chagas Disease Treatment Online Pharmacies , by Region USD Million (2016-2021)
  • Table 22. South America Chagas Disease Treatment, by Country USD Million (2016-2021)
  • Table 23. South America Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 24. South America Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 25. South America Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 26. South America Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 27. South America Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 28. South America Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 29. Brazil Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 30. Brazil Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 31. Brazil Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 32. Brazil Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 33. Brazil Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 34. Brazil Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 35. Argentina Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 36. Argentina Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 37. Argentina Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 38. Argentina Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 39. Argentina Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 40. Argentina Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 41. Rest of South America Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 42. Rest of South America Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 43. Rest of South America Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 44. Rest of South America Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 45. Rest of South America Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 46. Rest of South America Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 47. Asia Pacific Chagas Disease Treatment, by Country USD Million (2016-2021)
  • Table 48. Asia Pacific Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 49. Asia Pacific Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 50. Asia Pacific Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 51. Asia Pacific Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 52. Asia Pacific Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 53. Asia Pacific Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 54. China Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 55. China Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 56. China Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 57. China Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 58. China Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 59. China Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 60. Japan Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 61. Japan Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 62. Japan Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 63. Japan Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 64. Japan Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 65. Japan Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 66. India Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 67. India Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 68. India Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 69. India Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 70. India Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 71. India Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 72. South Korea Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 73. South Korea Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 74. South Korea Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 75. South Korea Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 76. South Korea Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 77. South Korea Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 78. Taiwan Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 79. Taiwan Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 80. Taiwan Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 81. Taiwan Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 82. Taiwan Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 83. Taiwan Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 84. Australia Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 85. Australia Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 86. Australia Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 87. Australia Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 88. Australia Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 89. Australia Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 90. Rest of Asia-Pacific Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 91. Rest of Asia-Pacific Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 92. Rest of Asia-Pacific Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 93. Rest of Asia-Pacific Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 94. Rest of Asia-Pacific Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 95. Rest of Asia-Pacific Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 96. Europe Chagas Disease Treatment, by Country USD Million (2016-2021)
  • Table 97. Europe Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 98. Europe Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 99. Europe Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 100. Europe Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 101. Europe Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 102. Europe Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 103. Germany Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 104. Germany Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 105. Germany Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 106. Germany Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 107. Germany Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 108. Germany Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 109. France Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 110. France Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 111. France Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 112. France Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 113. France Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 114. France Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 115. Italy Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 116. Italy Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 117. Italy Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 118. Italy Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 119. Italy Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 120. Italy Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 121. United Kingdom Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 122. United Kingdom Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 123. United Kingdom Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 124. United Kingdom Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 125. United Kingdom Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 126. United Kingdom Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 127. Netherlands Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 128. Netherlands Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 129. Netherlands Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 130. Netherlands Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 131. Netherlands Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 132. Netherlands Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 133. Rest of Europe Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 134. Rest of Europe Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 135. Rest of Europe Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 136. Rest of Europe Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 137. Rest of Europe Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 138. Rest of Europe Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 139. MEA Chagas Disease Treatment, by Country USD Million (2016-2021)
  • Table 140. MEA Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 141. MEA Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 142. MEA Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 143. MEA Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 144. MEA Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 145. MEA Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 146. Middle East Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 147. Middle East Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 148. Middle East Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 149. Middle East Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 150. Middle East Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 151. Middle East Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 152. Africa Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 153. Africa Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 154. Africa Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 155. Africa Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 156. Africa Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 157. Africa Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 158. North America Chagas Disease Treatment, by Country USD Million (2016-2021)
  • Table 159. North America Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 160. North America Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 161. North America Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 162. North America Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 163. North America Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 164. North America Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 165. United States Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 166. United States Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 167. United States Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 168. United States Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 169. United States Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 170. United States Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 171. Canada Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 172. Canada Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 173. Canada Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 174. Canada Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 175. Canada Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 176. Canada Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 177. Mexico Chagas Disease Treatment, by Type USD Million (2016-2021)
  • Table 178. Mexico Chagas Disease Treatment, by Application USD Million (2016-2021)
  • Table 179. Mexico Chagas Disease Treatment, by Drugs USD Million (2016-2021)
  • Table 180. Mexico Chagas Disease Treatment, by Treatment USD Million (2016-2021)
  • Table 181. Mexico Chagas Disease Treatment, by Route of Administration USD Million (2016-2021)
  • Table 182. Mexico Chagas Disease Treatment, by Distribution Channel USD Million (2016-2021)
  • Table 183. Company Basic Information, Sales Area and Its Competitors
  • Table 184. Company Basic Information, Sales Area and Its Competitors
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Chagas Disease Treatment: by Type(USD Million)
  • Table 194. Chagas Disease Treatment Acute Chagas Disease , by Region USD Million (2022-2027)
  • Table 195. Chagas Disease Treatment Chronic Chagas Disease , by Region USD Million (2022-2027)
  • Table 196. Chagas Disease Treatment: by Application(USD Million)
  • Table 197. Chagas Disease Treatment Hospitals , by Region USD Million (2022-2027)
  • Table 198. Chagas Disease Treatment Homecare , by Region USD Million (2022-2027)
  • Table 199. Chagas Disease Treatment Specialty Clinics , by Region USD Million (2022-2027)
  • Table 200. Chagas Disease Treatment Others , by Region USD Million (2022-2027)
  • Table 201. Chagas Disease Treatment: by Drugs(USD Million)
  • Table 202. Chagas Disease Treatment Benznidazole , by Region USD Million (2022-2027)
  • Table 203. Chagas Disease Treatment Nifurtimox , by Region USD Million (2022-2027)
  • Table 204. Chagas Disease Treatment: by Treatment(USD Million)
  • Table 205. Chagas Disease Treatment Antiparasitic Treatment , by Region USD Million (2022-2027)
  • Table 206. Chagas Disease Treatment Symptomatic Treatment , by Region USD Million (2022-2027)
  • Table 207. Chagas Disease Treatment: by Route of Administration(USD Million)
  • Table 208. Chagas Disease Treatment Oral , by Region USD Million (2022-2027)
  • Table 209. Chagas Disease Treatment Injectable , by Region USD Million (2022-2027)
  • Table 210. Chagas Disease Treatment: by Distribution Channel(USD Million)
  • Table 211. Chagas Disease Treatment Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 212. Chagas Disease Treatment Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 213. Chagas Disease Treatment Online Pharmacies , by Region USD Million (2022-2027)
  • Table 214. South America Chagas Disease Treatment, by Country USD Million (2022-2027)
  • Table 215. South America Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 216. South America Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 217. South America Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 218. South America Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 219. South America Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 220. South America Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 221. Brazil Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 222. Brazil Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 223. Brazil Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 224. Brazil Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 225. Brazil Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 226. Brazil Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 227. Argentina Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 228. Argentina Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 229. Argentina Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 230. Argentina Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 231. Argentina Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 232. Argentina Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 233. Rest of South America Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 234. Rest of South America Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 235. Rest of South America Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 236. Rest of South America Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 237. Rest of South America Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 238. Rest of South America Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 239. Asia Pacific Chagas Disease Treatment, by Country USD Million (2022-2027)
  • Table 240. Asia Pacific Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 241. Asia Pacific Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 242. Asia Pacific Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 243. Asia Pacific Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 244. Asia Pacific Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 245. Asia Pacific Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 246. China Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 247. China Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 248. China Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 249. China Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 250. China Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 251. China Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 252. Japan Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 253. Japan Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 254. Japan Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 255. Japan Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 256. Japan Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 257. Japan Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 258. India Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 259. India Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 260. India Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 261. India Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 262. India Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 263. India Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 264. South Korea Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 265. South Korea Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 266. South Korea Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 267. South Korea Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 268. South Korea Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 269. South Korea Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 270. Taiwan Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 271. Taiwan Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 272. Taiwan Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 273. Taiwan Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 274. Taiwan Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 275. Taiwan Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 276. Australia Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 277. Australia Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 278. Australia Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 279. Australia Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 280. Australia Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 281. Australia Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 282. Rest of Asia-Pacific Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 283. Rest of Asia-Pacific Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 284. Rest of Asia-Pacific Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 285. Rest of Asia-Pacific Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 286. Rest of Asia-Pacific Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 287. Rest of Asia-Pacific Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 288. Europe Chagas Disease Treatment, by Country USD Million (2022-2027)
  • Table 289. Europe Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 290. Europe Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 291. Europe Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 292. Europe Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 293. Europe Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 294. Europe Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 295. Germany Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 296. Germany Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 297. Germany Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 298. Germany Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 299. Germany Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 300. Germany Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 301. France Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 302. France Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 303. France Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 304. France Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 305. France Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 306. France Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 307. Italy Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 308. Italy Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 309. Italy Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 310. Italy Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 311. Italy Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 312. Italy Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 313. United Kingdom Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 314. United Kingdom Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 315. United Kingdom Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 316. United Kingdom Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 317. United Kingdom Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 318. United Kingdom Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 319. Netherlands Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 320. Netherlands Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 321. Netherlands Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 322. Netherlands Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 323. Netherlands Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 324. Netherlands Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 325. Rest of Europe Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 326. Rest of Europe Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 327. Rest of Europe Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 328. Rest of Europe Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 329. Rest of Europe Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 330. Rest of Europe Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 331. MEA Chagas Disease Treatment, by Country USD Million (2022-2027)
  • Table 332. MEA Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 333. MEA Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 334. MEA Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 335. MEA Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 336. MEA Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 337. MEA Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 338. Middle East Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 339. Middle East Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 340. Middle East Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 341. Middle East Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 342. Middle East Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 343. Middle East Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 344. Africa Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 345. Africa Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 346. Africa Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 347. Africa Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 348. Africa Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 349. Africa Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 350. North America Chagas Disease Treatment, by Country USD Million (2022-2027)
  • Table 351. North America Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 352. North America Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 353. North America Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 354. North America Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 355. North America Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 356. North America Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 357. United States Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 358. United States Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 359. United States Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 360. United States Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 361. United States Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 362. United States Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 363. Canada Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 364. Canada Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 365. Canada Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 366. Canada Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 367. Canada Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 368. Canada Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 369. Mexico Chagas Disease Treatment, by Type USD Million (2022-2027)
  • Table 370. Mexico Chagas Disease Treatment, by Application USD Million (2022-2027)
  • Table 371. Mexico Chagas Disease Treatment, by Drugs USD Million (2022-2027)
  • Table 372. Mexico Chagas Disease Treatment, by Treatment USD Million (2022-2027)
  • Table 373. Mexico Chagas Disease Treatment, by Route of Administration USD Million (2022-2027)
  • Table 374. Mexico Chagas Disease Treatment, by Distribution Channel USD Million (2022-2027)
  • Table 375. Research Programs/Design for This Report
  • Table 376. Key Data Information from Secondary Sources
  • Table 377. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chagas Disease Treatment: by Type USD Million (2016-2021)
  • Figure 5. Global Chagas Disease Treatment: by Application USD Million (2016-2021)
  • Figure 6. Global Chagas Disease Treatment: by Drugs USD Million (2016-2021)
  • Figure 7. Global Chagas Disease Treatment: by Treatment USD Million (2016-2021)
  • Figure 8. Global Chagas Disease Treatment: by Route of Administration USD Million (2016-2021)
  • Figure 9. Global Chagas Disease Treatment: by Distribution Channel USD Million (2016-2021)
  • Figure 10. South America Chagas Disease Treatment Share (%), by Country
  • Figure 11. Asia Pacific Chagas Disease Treatment Share (%), by Country
  • Figure 12. Europe Chagas Disease Treatment Share (%), by Country
  • Figure 13. MEA Chagas Disease Treatment Share (%), by Country
  • Figure 14. North America Chagas Disease Treatment Share (%), by Country
  • Figure 15. Global Chagas Disease Treatment share by Players 2021 (%)
  • Figure 16. Global Chagas Disease Treatment share by Players (Top 3) 2021(%)
  • Figure 17. Global Chagas Disease Treatment share by Players (Top 5) 2021(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Humanigen, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 20. Humanigen, Inc (United States) Revenue: by Geography 2021
  • Figure 21. Savant HWP, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 22. Savant HWP, Inc (United States) Revenue: by Geography 2021
  • Figure 23. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 25. Eisai Co., Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Eisai Co., Ltd (Japan) Revenue: by Geography 2021
  • Figure 27. Oblita Therapeutics (Belgium) Revenue, Net Income and Gross profit
  • Figure 28. Oblita Therapeutics (Belgium) Revenue: by Geography 2021
  • Figure 29. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2021
  • Figure 31. Collaborations Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 32. Collaborations Pharmaceuticals, Inc (United States) Revenue: by Geography 2021
  • Figure 33. Astellas Pharma Inc (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Astellas Pharma Inc (Japan) Revenue: by Geography 2021
  • Figure 35. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 36. Sanofi (France) Revenue: by Geography 2021
  • Figure 37. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc (United States) Revenue: by Geography 2021
  • Figure 39. Global Chagas Disease Treatment: by Type USD Million (2022-2027)
  • Figure 40. Global Chagas Disease Treatment: by Application USD Million (2022-2027)
  • Figure 41. Global Chagas Disease Treatment: by Drugs USD Million (2022-2027)
  • Figure 42. Global Chagas Disease Treatment: by Treatment USD Million (2022-2027)
  • Figure 43. Global Chagas Disease Treatment: by Route of Administration USD Million (2022-2027)
  • Figure 44. Global Chagas Disease Treatment: by Distribution Channel USD Million (2022-2027)
  • Figure 45. South America Chagas Disease Treatment Share (%), by Country
  • Figure 46. Asia Pacific Chagas Disease Treatment Share (%), by Country
  • Figure 47. Europe Chagas Disease Treatment Share (%), by Country
  • Figure 48. MEA Chagas Disease Treatment Share (%), by Country
  • Figure 49. North America Chagas Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Humanigen, Inc (United States)
  • Savant HWP, Inc (United States)
  • Bayer AG (Germany)
  • Eisai Co., Ltd (Japan)
  • Oblita Therapeutics (Belgium)
  • GlaxoSmithKline plc (United Kingdom)
  • Collaborations Pharmaceuticals, Inc (United States)
  • Astellas Pharma Inc (Japan)
  • Sanofi (France)
  • Pfizer Inc (United States)
Additional players considered in the study are as follows:
Epichem Pty Ltd (Australia) , DAIICHI SANKYO COMPANY, LIMITED (Japan) , Novartis AG (Switzerland) , Kancera AB (Sweden) , AstraZeneca (United Kingdom) , Maprimed S.A. (Argentina)
Select User Access Type

Key Highlights of Report


Apr 2022 200 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Chagas Disease Treatment Quantitative research analysis
Global (United States, European Union and China) Chagas Disease Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Large scape Population Movements Mostly from Ruler Urban Areas of the World Have Increased the Geographic Distribution of the Chagas Disease " is seen as one of major growth factors of Chagas Disease Treatment Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Chagas Disease Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global (United States, European Union and China) Chagas Disease Treatment Report?

Have a Query? Click Here

Other Related Reports

Conjunctivitis Drugs Comprehensive Study by Type (Antibiotics, Mast Cell Stabilizers, Steroids, Others), Application (Hospitals, Self-Administered), Route of Administration (Topical, Oral, Intra-Vitr...
$ 3450
Cyclobenzaprine Drug Comprehensive Study by Type (Tablet, Capsule), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), End-user (Hospitals, Clinics, Others) Players and Re...
$ 3500
Marine Biomedicine Comprehensive Study by Type (Marine Animal, Marine Plant), Application (Analgesic, Anticancer, Anti-inflammatory, Antimalarial, Antimicrobial, Bone grafting, Health Care Products),...
$ 3750
Tipranavir Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Dosage (Oral Solution (100 mg/mL), Capsule (250 mg)) Players and Region - G...
$ 3500
Levocetirizine Drug Comprehensive Study by Type (Tablets, Oral Solution), Application (Allergic Rhinitis, Chronic Hives (Urticaria), Renal impairment, Hepatic impairment), Distribution Channel (Hospi...
$ 3450
Exenatide Comprehensive Study by Type (Extended-release injectable suspension, Fast release injectable suspension), Application (Hospital, Drug store) Players and Region - Global Market Outlook to 20...
$ 3500